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To deﬁ  ne the prevalence of pilus islet 2 (PI-2)–encoded 
pili in Streptococcus pneumoniae in a geographically de-
ﬁ  ned area, we examined 590 S. pneumoniae isolates from 
population-based surveillance of invasive pneumococcal 
disease in Atlanta, Georgia, USA, 1994–2006. In 2006, PI-2 
was present in 21% of all invasive isolates, including sero-
types 1 (100%), 7F (89%), 11A (21%), 19A (40%), and 19F 
(75%). Only serotype 19F is included in the 7-valent pneu-
mococcal conjugate vaccine that is in use worldwide. In 
1999, PI-2-containing isolates were of the same serotypes 
but accounted for only 3.6% of all invasive isolates. The 
increase of PI-2 in 2006 resulted predominantly from the 
emergence of serotype 19A isolates of sequence type 320 
and the expansion of serotype 7F isolates. The increase 
in PI-2-containing isolates and the ﬁ  nding that isolates of 
all identiﬁ  ed serotypes expressed highly conserved PI-2 pili 
supports their potential as a vaccine candidate.
S
treptococcus pneumoniae is a major human pathogen, 
which causes pneumonia, sinusitis, otitis, bacterial men-
ingitis, and septicemia. Introduction of the 7-valent pneu-
mococcal conjugate vaccine (PCV7, Prevnar; Wyeth, Mad-
ison, NJ, USA) in 2000 has dramatically decreased invasive 
pneumococcal disease in the United States in children and 
in adults (1) and is now in use worldwide. PCV7 includes 
capsule polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F, 
and 23F, serotypes that were responsible for >80% of cases 
of invasive pneumococcal disease in the United States be-
fore the introduction of the conjugate vaccine (1). In recent 
years other non-PCV7 serotypes, including 7F and 19A, 
have been emerging in the United States, (2–4).
Pili have recently been identiﬁ  ed on several gram-
positive bacteria (5–7). To date, 2 different pilus islets 
(PIs) have been described in S. pneumoniae that encode the 
structural and biosynthetic genes for 2 antigenically differ-
ent types of pili, PI-1 (8) and recently described PI-2 (9). 
The so-called rlrA pathogenicity islet (10) or PI-1 is a 14-
kb genetic region present in 21%–27% of clinical isolates, 
depending on the geographic region analyzed. It is most 
prevalent in, but not restricted to, the PCV7-vaccine sero-
types 4, 6B, 9V, 14, and 19F (11–13).
PI-2 is a 7-kb region located between the genes that 
encode peptidase T (PepT) and ferrochelatase (HemH) (9). 
The region is composed of 5 genes, which encode 2 sur-
face proteins, PitA and PitB, with pitA a pseudogene due 
to a stop-codon in the N terminus, a signal peptidase-like 
protein (SipA), and 2 sortases (SrtG1 and SrtG2); the lat-
ter is nonfunctional in most of the strains (9). This PI has 
been reported to be present in ≈16% of the analyzed iso-
lates belonging to serotypes 1, 2, 7F, 19A, and 19F (9). The 
presence of PI-2 pili appears to be a clonal property, rather 
than serotype associated, an observation that has been de-
scribed for PI-1 as well (11–13). For isolates of serotype 
19A, PI-2–containing isolates have been shown to be as-
sociated with sequence type (ST) ST320, a clone related 
to the worldwide distributed multidrug-resistant serotype 
19F clone Taiwan19F-14 (4,14). ST320 belongs to clonal 
complex (CC) CC271 (with ST271 as the predicted found-
er of this CC); isolates of this CC have been shown to en-
code both PIs and express both pili concomitantly on their 
surface (9).
The PI-2 pilus is composed of polymers of the major 
pilus protein PitB (9). In contrast to other pili in gram-
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positive bacteria that contain accessory pilus proteins, that 
serve as adhesins (15–17) or adaptors for pilus attachment 
to the cell wall (18,19), PI-2 pili appear to consist solely of 
PitB polymers, and these polymers themselves have been 
shown to mediate adhesion of S. pneumoniae to eukaryotic 
cells (9).
Bagnoli et al. identiﬁ  ed PI-2–containing isolates in a 
random, worldwide collection of pneumococcal isolates 
(9). We describe the distribution of PI-2 pili in a well-
documented, comprehensive collection from a deﬁ  ned geo-
graphic region, i.e., in invasive pneumococcal isolates col-
lected as part of a population-based surveillance program 
conducted in the metropolitan area of Atlanta, Georgia, 
USA.
Materials and Methods
Strain Collection
A set of 590 strains of S. pneumoniae from population-
based surveillance of invasive pneumococcal disease iso-
lated between 1994 and 2006 in the 8-county metropolitan 
Atlanta area, Georgia Health District 3 formed the basis 
for this study. The isolates were obtained as a part of the 
Centers for Disease Control and Prevention–sponsored Ac-
tive Bacterial Core surveillance of the Georgia Emerging 
Infections Program (1,20). Information about serotype and 
antimicrobial drug susceptibility was determined for all 
isolates as described (21). Only viable strains with docu-
mented serotype and available antibiogram were included 
in the study. Laboratory strain S. pneumoniae R6 is a non-
encapsulated derivative of the serotype 2 strain D39 (22).
PCR-based Screening for PI-2
To ascertain whether PI-2 was absent from the de-
scribed insertion site (9), we designed primers pepT_F and 
hemH_R (Table 1) against the ﬂ  anking genes pepT and 
hemH. To determine whether PI-2 was present, we used 
primers sipA_up and sipA_dn (Table 1) designed against 
the PI-2–speciﬁ  c gene sipA. We tested for PI-1 using prim-
ers Rlr_up_F and Rlr_do_R for its absence and Rlr_SrtC_F 
and Rlr_srtD_R for its presence, respectively (Table 1).
Multilocus Sequence Typing and Clonal Complexes
Multilocus sequence typing (MLST) was performed as 
described (23). CCs were assigned by using the eBurst pro-
gram (24) to partition the MLST database (http://spneumo-
niae.mlst.net). The predicted founder of a CC was assigned 
by eBurst to the ST with the highest number of single-locus 
variants.
Construction of a pitB-Deletion Mutant
The 3′- and 5′-ﬂ  anking regions of pitB were ampli-
ﬁ   ed by using primer pairs sipA_up_F/PilA_del_3 and 
PilA_del_2/SrtC_do_R (Table 1). Both PCR products were 
used in a PCR-based overlap-extension reaction, which in-
troduced an MfeI restriction site between the 2 fused frag-
ments. The PCR product was cloned into pCR-Blunt II 
(Invitrogen, Carlsbad, CA, USA), resulting in pCR-pitB. 
The erm-cassette of pSK-erm (25) was ampliﬁ  ed by using 
primers erm_F and erm_R (Table 1) and ligated into MfeI-
digested pCR-pitB. The resulting plasmid, pCR-pitB:erm, 
was used to transform GA41070 according to established 
protocols (26), which resulted in mutant GA41070ΔpitB.
Production of Recombinant PitB and Antiserum
The region of pitB that encoded the mature protein (bp 
126–bp 1128) was ampliﬁ  ed from chromosomal DNA of 
serotype 1 strain GA19686 and cloned into the Escheri-
chia coli expression vector pET-32a+ (Stratagene, La 
Jolla, CA, USA). The thioredoxin/6xHis-PitB fusion pro-
tein was puriﬁ  ed by using the B-PER 6xHis Fusion Puri-
ﬁ  cation Kit (Pierce, Rockford, IL, USA). The N-terminal 
thioredoxin/6xhis-tag was removed by cleavage with re-
combinant enterokinase (Novagen, Madison, WI, USA) 
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Table 1. Primers used in this study of invasive Streptococcus pneumoniae isolates, Atlanta, Georgia, USA, 1994–2006*† 
Region  Primer  Sequence (5ƍ o 3ƍ)‡ 
Erm cassette  erm_F  gctctagaCGTTAGATTAATTCCTACCAGTGAC
 erm_R  gctctagaCTCCATTCCCTTTAGTAACGTGTAAC
PI-2  pepT_F  TAAGAAGCGGTCCAAGAGATTTGG 
 hemH_R  AATAATGGGGCTCCAAAATCAAGC 
 sipA_up_F  CTCTAGGAGGGATCTTCTTTATCATC 
 sipA_do_R  CTACAGCCGTTGTTCGATTGTCC 
 PilA_del_3  gcaattgcccgggcctagCCTGTATAGGGATGGTTCCAAAAG
 PilA_del_2  ctaggcccgggcaattgcGCTGGGGGCAGATGATG
 Rlr_up_F  CTTCCACGAAGTTCTTTCAATGG 
PI-1  Rlr_do_R  GTCTTAGAATATCATGGTTTACGTGC 
 Rlr_srtC_F  GGGGAAGATTATGCGACCTT 
 Rlr_srtD_R  GCTTGGCTCTGCACGGTGCC 
*PI, pilus islet. 
†Not included are primers used for sequencing and multilocus sequence typing. 
‡Lowercase letters represent bases added for mutagenesis; uppercase letters represent bases complementary to S. pneumoniae. PI-2 Pili of Streptococcus pneumoniae
according to the manufacturer’s recommendations. Puri-
ﬁ  ed PitB was used to produce a rabbit polyclonal antiserum 
(Covance Research Products Inc., Princeton, NJ, USA).
Preparation of Cell Wall Extracts from S. pneumoniae
Cultures were grown to mid-exponential phase (opti-
cal density600 0.5–0.6) in Todd-Hewitt medium containing 
0.5% yeast extract. After centrifugation, the cell pellets 
were resuspended in 1/20 of the culture volume in extrac-
tion buffer (50 mmol/LTris-HCl; pH 8.0) containing 200 
U/mL mutanolysin (Sigma-Aldrich, St. Louis, MO, USA) 
and 30% rafﬁ  nose. After 2 h of incubation at 30°C, cell 
wall extracts were collected by centrifugation at 12,000 × g 
for 15 min; 20 μL cell wall extract were mixed with sodium 
dodecyl sulfate–polyacryamide gel electrophoresis sample 
buffer and boiled for 10 min immediately before separation 
on a 4%–12% Tris-HCl polyacrylamide gel (NuPAGE; In-
vitrogen). For immunostaining, proteins were transferred 
to a nitrocellulose membrane and detected with polyclonal 
anti-PitB antiserum at a dilution of 1:20,000.
Statistical Analysis
Proportions were compared by using the Fisher exact 
test. p values <0.005 were considered signiﬁ  cant.
Results
PI-2 in Strains of Serotypes 1, 7F, 11A, 19A, and 19F
To determine the post PCV-7 prevalence of PI-2 in S. 
pneumoniae, we analyzed all 381 viable and documented 
invasive isolates collected in 2006 in metropolitan Atlanta 
(381/409) in a PCR-based screen. Two PCRs were per-
formed with each strain; 1 resulted in a PCR product in 
strains that lacked PI-2, and a second resulted in a product 
only in strains that contained PI-2. Strains that produced a 
PCR product for PI-2 were further characterized by ampli-
ﬁ  cation of pitB, which encoded the pilus backbone protein. 
For all strains, 1 of the 2 PCRs resulted in a PCR product. 
No strain gave a PCR product for both PCRs, which could 
have indicated the presence of the PI in an alternative in-
tegration site. These results strongly suggest that the pepT-
hemH intergenic region is the only integration site of PI-2 
in S. pneumoniae. Overall, 21% of all viable isolates col-
lected in 2006 contained PI-2. The PI-2 of S. pneumoniae 
strain GA47784 was assigned the GenBank accession no. 
GU256423.
PI-2 was identiﬁ  ed only in isolates of serotypes 1, 7F, 
11A, 19A, and 19F (Figure 1). Serotypes 19A and 7F were 
the most frequent PI-2–containing serotypes isolated in 
2006, with a PI-2 prevalence of 40% and 89%, respectively. 
In serotype 11A, PI-2 was identiﬁ  ed sporadically, whereas 
for serotype 19F, 75% of the isolates contained PI-2. Se-
rotype 1 was represented by a single isolate in 2006. To 
determine the prevalence of PI-2 in serotype 1 isolates, we 
analyzed an additional 20 invasive isolates, collected in At-
lanta from 1994 through 2005; all contained PI-2. Serotype 
1 had the highest presence of PI-2 of all analyzed serotypes. 
Except for serotype 19F, the PI-2–containing serotypes are 
not included in PCV7.
To further characterize PI-2 of a serotype 11A strain, 
we sequenced the 7-kb region between the ﬂ  anking genes 
pepT and hemH of strain GA47784. The sequence was 
99.9% identical to the published PI-2 sequences, with the 
highest sequence identity to serotype 1 strain PN110, with 
only 1-bp difference over the entire PI-2 region. The mu-
tation was located downstream of the stop-codon in pitA, 
which results in premature termination of PitA, as has been 
reported (9).
Effects of PCV7 Introduction on PI-2 Distribution
To assess whether PI-2 was associated with the emer-
gence of serotypes in the aftermath of PCV7 introduction 
(2000), the PI-2 distribution was determined in invasive 
isolates from 1999 that belonged to the PI-2–containing 
serotypes (Figure 2). The numbers of isolates for the dif-
ferent serotypes in the 2 periods reﬂ  ected the expansion of 
isolates of the nonvaccine serotypes 7F and 19A and the 
decline in 19F isolates (Figure 2) that has been described in 
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Figure 1. Frequency of pilus islet 
2 (PI-2)–containing Streptococcus 
pneumoniae invasive isolates in 
metropolitan Atlanta, Georgia, USA, 
2006. Black, PI-2–containing isolates; 
white, PI-2–lacking isolates. *Serotypes 
included in the 7-valent pneumococcal 
conjugate vaccine. RESEARCH
the United States since the introduction of PCV7 (4). PI-2 
was present in isolates of all 5 serotypes before the intro-
duction of PCV7; hence, PI-2 was not recently acquired. 
For serotype 7F, the ratio between PI-2–containing and PI-
2–lacking isolates in 2006 compared to the ratio in 1999 
remained essentially the same (Figure 2), which suggests 
that PI-2 pili may not provide a major selective advantage 
to invasive 7F isolates. Serotype 19A showed a signiﬁ  cant 
increase in PI-2–containing isolates. To assess the presence 
of PI-2 in other serotypes in 1999, we analyzed isolates of 
all represented serotypes of PI-2: all isolates of infrequent 
serotypes (1, 5, 7C, 7F, 8, 9A, 9N, 10A, 13, 15B, 15C, 16, 
16F, 18F, 20, 23A, 24B, 31, 33F, 34, 35B, 35F, 37) and at 
least 10% of the isolates of serotypes with >10 isolates (3, 
4, 6A, 6B, 9V, 11A, 12F, 14, 18C, 19A, 19F, 22F, 23F). No 
additional PI-2–containing isolates were detected, which 
suggests that serotypes 1, 7F, 11A, 19A, and 19F were the 
only serotypes that contained substantial numbers of PI-
2–containing isolates. These PI-2–containing isolates ac-
counted for ≈3.6% of all viable isolates collected in 1999. 
The estimation of total viable isolates in 1999 was based on 
the known proportion of viable isolates to total collected 
isolates of the PI-2–containing serotypes of 1999 (93%).
Genetic Relationships Between 
PI-2–containing Strains
To analyze the clonality of the PI-2–containing iso-
lates, we performed MLST for all PI-2–containing isolates 
from 1999 and 2006 (Table 2). For serotype 1, the isolates 
from 1999 and 2006 belonged to ST304 and ST227, re-
spectively (Table 2). Both STs have been described as the 
most prevalent serotype 1 STs in the United States (27,28). 
PI-2–containing serotype 7F isolates of 2006 belonged to 
either ST191 or ST1176, and ST191 isolates were respon-
sible for the strong expansion of this serotype in 2006. 7F 
isolates lacking PI-2 were tested and found to be of ST191 
(data not shown), which indicated that PI-2 is present in 
only a subpopulation of this ST. ST1176 is unrelated to 
ST191, and 7F isolates of this ST were not present in 1999. 
All PI-2–containing isolates of serotype 11A belonged to 
ST62. Analysis of additional serotype 11A isolates that 
lacked PI-2 showed that they all belonged to ST62 (data 
not shown). This ﬁ  nding suggests that the structure of this 
serotype is clonally homogeneous and that PI-2 is present 
in a subset of this ST.
For serotype 19A, 27 of the 39 PI-2–containing 19A 
isolates in 2006 were ST320 (Table 2). This ST was absent 
in 1999 (29); thus these isolates were the major contributor 
to the increase of PI-2–containing isolates of serotype 19A 
in 2006. Additionally, PI-2 was identiﬁ  ed in 19A isolates 
of ST1339 and ST2268, and both sequence types belonged 
to CC2090. One ST1339 isolate was present in 1999, which 
indicated that PI-2 was present in this ST before PCV7 was 
introduced. 19A isolates of 2006 that lacked PI-2 were 
tested and found to belong to other STs, e.g., ST199 and 
ST695, STs consistent with the described population struc-
ture of 19A isolates in the United States (4).
ST analysis of the remaining isolates of 19F isolates 
in 2006 showed that PI-2 was present in isolates that be-
longed to CC271 (ST236, ST651, ST3039) and also in 
the unrelated CC251 (ST251, ST654, ST1258) (Table 2). 
However, analysis of several 19F isolates that lacked PI-2 
revealed isolates of ST3039 (data not shown); this ﬁ  nding 
indicated either a loss of PI-2 or a recent acquisition of the 
islet in a subset of isolates of this ST. Isolates of CC271 
have been described to encode and express PI-1 and PI-2 
concomitantly (9). Analysis for the presence of PI-1 in our 
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Figure 2. Percentage of pilus islet 2 (PI-2)–containing Streptococcus 
pneumoniae invasive isolates among serotypes associated with 
PI-2 in metropolitan Atlanta, Georgia, USA, 1999 and 2006. The 
total number of isolates for each serotype is shown at the top of 
the column. *Signiﬁ  cant difference between 1999 and 2006 19A 
isolates (p<0.005). 
Table 2. Clonal distribution of PI-2-containing Streptococcus 
pneumoniae isolates, Atlanta, Georgia, USA, 1994–2006* 
Serotype CC ST
No. PI-2-containing isolates 
1999 2006
1 304 304 1 1
306 227 (DLV) 3 –
7F 191 191 3 28
218 1176 (DLV) – 3
11A 53 62 2 3
19A 2090 1339 (SLV) 1 9
2268 (DLV) – 3
271 320 (SLV) – 27
19F 271 271 1 –
236 (SLV) 3 1
3039 (SLV) –1
651 (DLV) 32
251 251 1 1
654 (SLV) 41
1258 (DLV) 2–
*CC, clonal complex; ST, sequence type; PI, pilus islet; DLV, double-locus 
variant; SLV, single-locus variant. PI-2 Pili of Streptococcus pneumoniae
population conﬁ  rmed PI-1 in isolates of CC271 (ST320, 
ST271, ST3039, ST236, ST651). Additionally, PCR results 
showed that PI-1 was in ST1339 isolates but not in isolates 
of the single locus variant ST2268. Isolates of all other PI-
2–containing serotypes or STs did not contain PI-1.
Antimicrobial Drug Resistance 
and PI-2–containing Isolates
19F and 19A isolates of CC271 are closely related to 
the globally distributed multidrug-resistant clone Taiwan19F-
14, and all were resistant to penicillin, erythromycin, cot-
rimoxazole, tetracycline, and chloramphenicol. In addition, 
serotype 19A isolates of CC2090 (ST1339, ST2268) were 
resistant to penicillin, erythromycin, and cotrimoxazole. 
All PI-2–containing 19A isolates in 2006 were multidrug 
resistant. In contrast, PI-2–containing isolates of serotypes 
1, 7F, 11A, and 19F (ST654, ST251) were susceptible to 
all tested antimicrobial drugs. Hence, antimicrobial drug 
resistance was not a consistent feature of PI-2–containing 
isolates.
Expression of High Molecular Weight PitB 
on the Surface of PI-2–containing Isolates
The  ﬁ  rst report of PI-2 pili described mutations in 
several genes encoded by PI-2 (namely, pitA and srtG2), 
which resulted in their inactivation (9). To conﬁ  rm that 
PI-2–containing isolates indeed express PitB polymers on 
their surface, we produced an anti-PitB antiserum to detect 
PitB polymers. The speciﬁ  city of the PitB antiserum was 
tested against cell wall extracts of strain GA41070 and its 
isogenic pitB deletion mutant, GA41070ΔpitB (Figure 3). 
In the wild type, the antibody reacted with several bands 
that produced the high molecular weight (HMW) banding 
pattern characteristic of gram-positive pili (30,31) (Figure 
3). As expected, the PitB monomer and the HMW banding 
pattern were absent in the pitB-deletion mutant (Figure 3).
To analyze whether the PI-2–containing isolates of the 
different STs produced PitB polymers, we used Western 
blots to examine their cell wall extracts (Figure 4). All PI-2
–containing strains showed the same HMW banding pattern 
(Figure 4, lanes 2–15). In addition, all 81 PI-2–containing 
isolates from 2006 were analyzed by whole cell dot blots 
that conﬁ  rmed that all isolates expressed PitB on their sur-
face (data not shown).
High Conservation of PitB among Different STs
To determine the degree of variation in PitB, we se-
quenced  pitB in isolates representing the different STs 
(Table 2). The pitB sequences were 100% identical for 
all strains, except the 7F isolates GA47077 (ST191) and 
GA47340 (ST1176), which have a single point mutation 
that has been observed in other serotype 7F strains (9). The 
high conservation of PitB was consistent with the reported 
PitB sequences by Bagnoli et al. (9) and is an essential 
feature of PI-2 as a potential vaccine candidate. Addition-
ally, we analyzed the gene for the second surface protein 
encoded in PI-2, pitA, and conﬁ  rmed the presence of the 
described stop-codon in all strains representing the differ-
ent STs (Table 2).
Discussion
PI-1 pili on S. pneumoniae have been reported as 
promising vaccine candidates for this important human 
pathogen (13,32). One limitation to this approach is that 
PI-1 has been found in only ≈25% of strains; it is most fre-
quently found in pneumococcal isolates of serotypes cov-
ered by PCV7, which are decreasing in countries that have 
introduced the vaccine. The recent identiﬁ  cation of PI-2 in 
serotypes not covered by PCV7 has raised the possibility 
that broad coverage of strains can be achieved by a bivalent 
pilus-based vaccine.
The ﬁ  rst report on PI-2 pili described the serotypes 
and sequence types associated with PI-2 (9). In the cur-
rent study, we deﬁ  ned the prevalence of PI-2–expressing 
isolates in a deﬁ  ned geographic region and population and 
assessed whether the introduction of PCV7 had an effect 
on the distribution of PI-2–containing isolates. Twenty-one 
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Figure 3. Detection of high molecular weight PitB polymers in 
invasive isolates of Streptococcus pneumoniae. Western blot of 
cell wall extracts from strains GA41070 (lane 1) and GA41070ΔpitB 
(lane 2) detected with anti-PitB antiserum. Monomeric PitB (arrow) 
and the marker sizes are indicated.  RESEARCH
percent of the 381 viable invasive pneumococcal isolates 
collected in 2006 in metropolitan Atlanta expressed PI-2 
pili. This percentage is higher than the PI-2 incidence re-
ported from a global strain collection (9) and is similar to 
the reported percentage for PI-1 (11–13). The higher inci-
dence rate of PI-2 in our study refers to a post-PCV7-era 
population, whereas the earlier report was based on a ran-
dom strain collection, including pre- and post-PCV7 iso-
lates. Therefore, our higher results are consistent with the 
assessment of Bagnoli et al. (9) that PI-2 is most prevalent 
in emerging, non-PCV7 serotypes.
Notably, all serotype 1 strains had PI-2. This sero-
type does not play a large role in pneumococcal invasive 
disease in the United States (27), a conclusion reﬂ  ected 
by the low number of serotype 1 isolates in our dataset. 
However, serotype 1 isolates have been identiﬁ  ed in sev-
eral studies as particularly invasive, in contrast to other 
serotypes that are more frequently associated with car-
riage (33–35) and associated with epidemic outbreaks 
(27,36,37). Further study of PI-2 prevalence in serotype 
1 requires a geographically different dataset with a higher 
serotype 1 prevalence.
In contrast to serotype 1, serotype 7F, together with 
19A, has been a major emerging serotype in the post-PCV7 
era (3,4), a fact reﬂ  ected in our dataset, with a 5-fold in-
crease between 1999 and 2006. Serotype 7F causes primary 
invasive disease in otherwise healthy patients and is found 
less frequently in carriers (33,35,38). As most of the sero-
type 7F isolates belong to ST191, the genetic structure of 
this serotype is very homogeneous (35). However, 3 iso-
lates of ST1176 were found in 2006. ST1176 belongs to 
CC218 and is unrelated to ST191. A 7F isolate of CC218 
had been observed in 1999 (29), a CC previously associated 
with isolates of serotype 12F. The ratio between PI-2–con-
taining and –lacking isolates of serotype 7F was essentially 
unchanged from 1999 to 2006; only the overall number of 
cases increased. Thus, PI-2 does not appear to provide a 
selective advantage to invasive serotype 7F isolates, i.e., 
contribute to the emergence of this serotype.
Serotype 11A has been described as an opportunistic 
serotype often found in asymptomatic carriers and a cause 
of disease in patients with underlying disease (33,35). How-
ever, when serotype 11A does cause invasive disease, it has 
been associated with a high number of deaths (35). Isolates 
that cause invasive disease have been identiﬁ  ed as belong-
ing to ST62, the ST most common among serotype 11A 
(35). The low prevalence of PI-2 in serotype 11A suggests 
that PI-2 pili are not essential for isolates of this serotype to 
cause invasive disease.
The genetic proﬁ  le of the serotype 19A isolates in At-
lanta is consistent with the described clonal distribution of 
this serotype in the United States in the post-PCV7 period 
(4). Several capsular switching events have contributed to 
the emergence of serotype 19A, including (but not limited 
to) ST320, originating from a multidrug-resistant deriva-
tive of clone Taiwan19F-14(ST236), and CC2090 (ST1339, 
ST2289) from the highly related clone North Carolina6A-23 
(39). Unlike serotype 7F, 19A is characterized by a hetero-
geneous clonal structure (4), and the presence of PI-2 is a 
feature of some of the clones.
Most of the PI-2–containing isolates that we found do 
belong to the serotypes reported for PI-2 by Bagnoli et al. 
(9). Serotype 2 was absent from our population during the 
surveillance period of 1994 to 2006, and in addition we 
identiﬁ  ed PI-2 in serotype 11A. Overall, we conﬁ  rmed the 
presence of PI-2 in emerging non-PCV7 serotypes. How-
ever, other non-PCV7 serotypes that do not have PI-2 are 
emerging as well, e.g., 15BCF, 22F, 33F, and 38 (2,40), 
which indicates that other mechanisms may inﬂ  uence the 
emergence of new serotypes.
Of note, 3 of the 4 non-PCV7 serotypes with PI-2–
containing isolates (serotypes 1, 7F, 19A) are included in 
the 13-valent pneumococcal conjugate vaccine now being 
introduced in Europe, Canada, and the United States. Use 
of this vaccine is expected to greatly reduce the frequency 
of all included serotypes and may thus reduce the propor-
tion of S. pneumoniae isolates that contain PI-2. In sum-
mary, the prevalence of PI-2 increased from ≈3.6% of the 
invasive pneumococcal isolates in 1999 to 21% in 2006 in 
metropolitan Atlanta, Georgia, especially in the emerging 
serotypes 7F and 19A. PI-2-containing isolates of all iden-
tiﬁ  ed sequence types expressed polymers of the highly con-
served pilus protein PitB on their surface. These ﬁ  ndings 
support the potential of PI-2 pili as a vaccine candidate.
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